Adial Pharmaceuticals (NASDAQ:ADIL)‘s stock had its “buy” rating reiterated by investment analysts at Brookline Capital Management in a research note issued to investors on Wednesday, The Fly reports. They presently have a $12.00 price target on the stock. Brookline Capital Management’s target price would indicate a potential upside of 200.75% from the company’s current price.
ADIL has been the topic of several other reports. Maxim Group reaffirmed a “buy” rating and set a $5.00 price target on shares of Adial Pharmaceuticals in a research report on Friday, August 20th. Litchfield Hills Research lifted their target price on shares of Adial Pharmaceuticals from $5.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, August 26th.
Adial Pharmaceuticals stock opened at $3.99 on Wednesday. Adial Pharmaceuticals has a one year low of $1.60 and a one year high of $5.08. The stock has a market cap of $80.99 million, a PE ratio of -3.87 and a beta of 0.67. The stock has a 50-day moving average of $3.87 and a two-hundred day moving average of $2.96.
Institutional investors have recently bought and sold shares of the company. Commonwealth Equity Services LLC boosted its holdings in Adial Pharmaceuticals by 31.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 29,050 shares of the company’s stock worth $74,000 after buying an additional 7,000 shares during the last quarter. Geode Capital Management LLC boosted its stake in Adial Pharmaceuticals by 13.2% during the 2nd quarter. Geode Capital Management LLC now owns 88,246 shares of the company’s stock worth $225,000 after purchasing an additional 10,261 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Adial Pharmaceuticals by 68.8% during the first quarter. Dimensional Fund Advisors LP now owns 31,410 shares of the company’s stock worth $76,000 after buying an additional 12,798 shares in the last quarter. Oppenheimer & Co. Inc. lifted its stake in shares of Adial Pharmaceuticals by 93.1% in the second quarter. Oppenheimer & Co. Inc. now owns 28,000 shares of the company’s stock worth $71,000 after buying an additional 13,500 shares in the last quarter. Finally, Barclays PLC purchased a new stake in Adial Pharmaceuticals during the 1st quarter valued at about $38,000. Institutional investors and hedge funds own 5.72% of the company’s stock.
Adial Pharmaceuticals Company Profile
Adial Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.
Featured Story: Do You Need a Fiduciary?
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.